Skip to main content
Top
Published in: Reproductive Biology and Endocrinology 1/2021

Open Access 01-12-2021 | Cystectomy | Research

Impact of perioperative use of GnRH agonist or dienogest on ovarian reserve after cystectomy for endometriomas: a randomized controlled trial

Authors: Ayako Muraoka, Satoko Osuka, Atsushi Yabuki, Bayasula, Masato Yoshihara, Hideaki Tanaka, Reina Sonehara, Natsuki Miyake, Mayuko Murakami, Sayako Yoshita, Natsuki Nakanishi, Tomoko Nakamura, Maki Goto, Akira Iwase, Hiroaki Kajiyama

Published in: Reproductive Biology and Endocrinology | Issue 1/2021

Login to get access

Abstract

Background

Ovarian endometrioma is a common gynecological disease that is often treated with surgery or hormonal treatment. Ovarian cystectomy, a surgical procedure for ovarian endometrioma, can result in impaired ovarian reserve.

Methods

We conducted a randomized controlled trial to evaluate the efficacy of hormonal treatment [gonadotropin-releasing hormone agonist (GnRHa) or dienogest (DNG)] for preserving ovarian reserve after cystectomy for ovarian endometrioma. The primary endpoint was the level of serum Anti-Müllerian hormone (AMH) as a marker of ovarian reserve.

Results

Before and after laparoscopic surgery, 22 patients in the GnRHa group and 27 patients in the DNG group were administered hormonal treatment for a total of 4 months. After 1-year follow-up, >60% of the patients in the DNG group retained over 70% of their pretreatment AMH levels, whereas no patient in the GnRHa group retained their AMH levels after cystectomy (P < 0.01). Interleukin-6 (IL-6) is a key cytokine involved in inflammation. Compared with the GnRHa group, patients in the DNG group had lower IL-6 levels at the end of treatment.

Conclusions

Our data revealed that DNG is more effective than GnRHa in preserving ovarian reserve after cystectomy of ovarian endometrioma. This is achieved through the reduction of the inflammatory response during the perioperative period and other endometriosis-related inflammatory reactions.

Trial registration

The registration number of this trial is UMIN-CTR, UMIN000018569, registered 6 August 2015, https://​upload.​umin.​ac.​jp/​cgi-open-bin/​ctr_​e/​ctr_​view.​cgi?​recptno=​R000021492, and Japan Registry of Clinical Trials, jRCTs041180140, registered 29 March 2019, https://​jrct.​niph.​go.​jp/​en-latest-detail/​jRCTs041180140. This randomized controlled trial was conducted in accordance with the CONSORT guidelines.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bulun SE, Yilmaz BD, Sison C, Miyazaki K, Bernardi L, Liu S, et al. Endometriosis. Endocr Rev. 2019;40(4):1048–79.CrossRef Bulun SE, Yilmaz BD, Sison C, Miyazaki K, Bernardi L, Liu S, et al. Endometriosis. Endocr Rev. 2019;40(4):1048–79.CrossRef
2.
go back to reference Raffi F, Metwally M, Amer S. The Impact of Excision of Ovarian Endometrioma on Ovarian Reserve: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metabolism. 2012;97(9):3146–54.CrossRef Raffi F, Metwally M, Amer S. The Impact of Excision of Ovarian Endometrioma on Ovarian Reserve: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metabolism. 2012;97(9):3146–54.CrossRef
3.
go back to reference Younis JS, Shapso N, Fleming R, Ben-Shlomo I, Izhaki I. Impact of unilateral versus bilateral ovarian endometriotic cystectomy on ovarian reserve: a systematic review and meta-analysis. Hum Reprod Update. 2019;25(3):375–91.CrossRef Younis JS, Shapso N, Fleming R, Ben-Shlomo I, Izhaki I. Impact of unilateral versus bilateral ovarian endometriotic cystectomy on ovarian reserve: a systematic review and meta-analysis. Hum Reprod Update. 2019;25(3):375–91.CrossRef
4.
go back to reference Iwase A, Nakamura T, Osuka S, Takikawa S, Goto M, Kikkawa F. Anti-Mullerian hormone as a marker of ovarian reserve: What have we learned, and what should we know? Reprod Med Biol. 2016;15(3):127–36.CrossRef Iwase A, Nakamura T, Osuka S, Takikawa S, Goto M, Kikkawa F. Anti-Mullerian hormone as a marker of ovarian reserve: What have we learned, and what should we know? Reprod Med Biol. 2016;15(3):127–36.CrossRef
5.
go back to reference La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, Artenisio AC, et al. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update. 2010;16(2):113–30.CrossRef La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, Artenisio AC, et al. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update. 2010;16(2):113–30.CrossRef
6.
go back to reference Sugita A, Iwase A, Goto M, Nakahara T, Nakamura T, Kondo M, et al. One-year follow-up of serum antimullerian hormone levels in patients with cystectomy: are different sequential changes due to different mechanisms causing damage to the ovarian reserve? Fertil Steril. 2013;100(2):516–22.CrossRef Sugita A, Iwase A, Goto M, Nakahara T, Nakamura T, Kondo M, et al. One-year follow-up of serum antimullerian hormone levels in patients with cystectomy: are different sequential changes due to different mechanisms causing damage to the ovarian reserve? Fertil Steril. 2013;100(2):516–22.CrossRef
7.
go back to reference Hirokawa W, Iwase A, Goto M, Takikawa S, Nagatomo Y, Nakahara T, et al. The post-operative decline in serum anti-Mullerian hormone correlates with the bilaterality and severity of endometriosis. Hum Reprod. 2011;26(4):904–10.CrossRef Hirokawa W, Iwase A, Goto M, Takikawa S, Nagatomo Y, Nakahara T, et al. The post-operative decline in serum anti-Mullerian hormone correlates with the bilaterality and severity of endometriosis. Hum Reprod. 2011;26(4):904–10.CrossRef
8.
go back to reference Iwase A, Nakamura T, Nakahara T, Goto M, Kikkawa F. Assessment of ovarian reserve using anti-Mullerian hormone levels in benign gynecologic conditions and surgical interventions: a systematic narrative review. Reprod Biol Endocrinol. 2014;12:125.CrossRef Iwase A, Nakamura T, Nakahara T, Goto M, Kikkawa F. Assessment of ovarian reserve using anti-Mullerian hormone levels in benign gynecologic conditions and surgical interventions: a systematic narrative review. Reprod Biol Endocrinol. 2014;12:125.CrossRef
9.
go back to reference Chen Y, Pei H, Chang Y, Chen M, Wang H, Xie H, et al. The impact of endometrioma and laparoscopic cystectomy on ovarian reserve and the exploration of related factors assessed by serum anti-Mullerian hormone: a prospective cohort study. J Ovarian Res. 2014;7:108.CrossRef Chen Y, Pei H, Chang Y, Chen M, Wang H, Xie H, et al. The impact of endometrioma and laparoscopic cystectomy on ovarian reserve and the exploration of related factors assessed by serum anti-Mullerian hormone: a prospective cohort study. J Ovarian Res. 2014;7:108.CrossRef
10.
go back to reference Iwase A, Osuka S, Goto M, Murase T, Nakamura T, Takikawa S, et al. Clinical application of serum anti-Mullerian hormone as an ovarian reserve marker: A review of recent studies. J Obstet Gynaecol Res. 2018;44(6):998–1006.CrossRef Iwase A, Osuka S, Goto M, Murase T, Nakamura T, Takikawa S, et al. Clinical application of serum anti-Mullerian hormone as an ovarian reserve marker: A review of recent studies. J Obstet Gynaecol Res. 2018;44(6):998–1006.CrossRef
11.
go back to reference Kovacevic VM, Andelic LM, Mitrovic Jovanovic A. Changes in serum antimullerian hormone levels in patients 6 and 12 months after endometrioma stripping surgery. Fertil Steril. 2018;110(6):1173–80.CrossRef Kovacevic VM, Andelic LM, Mitrovic Jovanovic A. Changes in serum antimullerian hormone levels in patients 6 and 12 months after endometrioma stripping surgery. Fertil Steril. 2018;110(6):1173–80.CrossRef
12.
go back to reference Grandi G, Mueller M, Bersinger NA, Cagnacci A, Volpe A, McKinnon B. Does dienogest influence the inflammatory response of endometriotic cells? A systematic review. Inflamm Res. 2016;65(3):183–92.CrossRef Grandi G, Mueller M, Bersinger NA, Cagnacci A, Volpe A, McKinnon B. Does dienogest influence the inflammatory response of endometriotic cells? A systematic review. Inflamm Res. 2016;65(3):183–92.CrossRef
13.
go back to reference Tsujioka H, Inoue Y, Emoto M, Sadamori R, Shirota K, Hachisuga T, et al. The efficacy of preoperative hormonal therapy before laparoscopic cystectomy of ovarian endometriomas. J Obstet Gynaecol Res. 2009;35(4):782–6.CrossRef Tsujioka H, Inoue Y, Emoto M, Sadamori R, Shirota K, Hachisuga T, et al. The efficacy of preoperative hormonal therapy before laparoscopic cystectomy of ovarian endometriomas. J Obstet Gynaecol Res. 2009;35(4):782–6.CrossRef
14.
go back to reference Iwabe T, Harada T, Sakamoto Y, Iba Y, Horie S, Mitsunari M, et al. Gonadotropin-releasing hormone agonist treatment reduced serum interleukin-6 concentrations in patients with ovarian endometriomas. Fertil Steril. 2003;80(2):300–4.CrossRef Iwabe T, Harada T, Sakamoto Y, Iba Y, Horie S, Mitsunari M, et al. Gonadotropin-releasing hormone agonist treatment reduced serum interleukin-6 concentrations in patients with ovarian endometriomas. Fertil Steril. 2003;80(2):300–4.CrossRef
15.
go back to reference Muzii L, Marana R, Caruana P, Mancuso S. The impact of preoperative gonadotropin-releasing hormone agonist treatment on laparoscopic excision of ovarian endometriotic cysts. Fertil Steril. 1996;65(6):1235–7.CrossRef Muzii L, Marana R, Caruana P, Mancuso S. The impact of preoperative gonadotropin-releasing hormone agonist treatment on laparoscopic excision of ovarian endometriotic cysts. Fertil Steril. 1996;65(6):1235–7.CrossRef
16.
go back to reference Kitajima M, Matsumoto K, Murakami N, Harada A, Kitajima Y, Masuzaki H, et al. Ovarian reserve after three-step laparoscopic surgery for endometriomas utilizing dienogest: A pilot study. Reprod Med Biol. 2020;19(4):425–31.CrossRef Kitajima M, Matsumoto K, Murakami N, Harada A, Kitajima Y, Masuzaki H, et al. Ovarian reserve after three-step laparoscopic surgery for endometriomas utilizing dienogest: A pilot study. Reprod Med Biol. 2020;19(4):425–31.CrossRef
17.
go back to reference Vercellini P, Vigano P, Somigliana E, Fedele L. Endometriosis: pathogenesis and treatment. Nat Rev Endocrinol. 2014;10(5):261–75.CrossRef Vercellini P, Vigano P, Somigliana E, Fedele L. Endometriosis: pathogenesis and treatment. Nat Rev Endocrinol. 2014;10(5):261–75.CrossRef
18.
go back to reference Ozaki R, Kumakiri J, Jinushi M, Ikuma S, Murakami K, Kawasaki Y, et al. Comparison of effect of preoperative dienogest and gonadotropin-releasing hormone agonist administration on laparoscopic cystectomy for ovarian endometriomas. Arch Gynecol Obstet. 2020;302(4):969–76.CrossRef Ozaki R, Kumakiri J, Jinushi M, Ikuma S, Murakami K, Kawasaki Y, et al. Comparison of effect of preoperative dienogest and gonadotropin-releasing hormone agonist administration on laparoscopic cystectomy for ovarian endometriomas. Arch Gynecol Obstet. 2020;302(4):969–76.CrossRef
19.
go back to reference Bedaiwy MA, Falcone T, Sharma RK, Goldberg JM, Attaran M, Nelson DR, et al. Prediction of endometriosis with serum and peritoneal fluid markers: a prospective controlled trial. Hum Reprod. 2002;17(2):426–31.CrossRef Bedaiwy MA, Falcone T, Sharma RK, Goldberg JM, Attaran M, Nelson DR, et al. Prediction of endometriosis with serum and peritoneal fluid markers: a prospective controlled trial. Hum Reprod. 2002;17(2):426–31.CrossRef
20.
go back to reference Ichioka M, Mita S, Shimizu Y, Imada K, Kiyono T, Bono Y, et al. Dienogest, a synthetic progestin, down-regulates expression of CYP19A1 and inflammatory and neuroangiogenesis factors through progesterone receptor isoforms A and B in endometriotic cells. J Steroid Biochem Mol Biol. 2015;147:103–10.CrossRef Ichioka M, Mita S, Shimizu Y, Imada K, Kiyono T, Bono Y, et al. Dienogest, a synthetic progestin, down-regulates expression of CYP19A1 and inflammatory and neuroangiogenesis factors through progesterone receptor isoforms A and B in endometriotic cells. J Steroid Biochem Mol Biol. 2015;147:103–10.CrossRef
21.
go back to reference Mita S, Shimizu Y, Notsu T, Imada K, Kyo S. Dienogest inhibits Toll-like receptor 4 expression induced by costimulation of lipopolysaccharide and high-mobility group box 1 in endometrial epithelial cells. Fertil Steril. 2011;96(6):1485–9.CrossRef Mita S, Shimizu Y, Notsu T, Imada K, Kyo S. Dienogest inhibits Toll-like receptor 4 expression induced by costimulation of lipopolysaccharide and high-mobility group box 1 in endometrial epithelial cells. Fertil Steril. 2011;96(6):1485–9.CrossRef
22.
go back to reference Zheng L, Kimura F, Wu D, Morimune A, Niwa Y, Mita S, et al. Dienogest suppresses the activation of primordial follicles and preserves the primordial follicle stockpile for fertility in mice. Reprod Biomed Online. 2018;36(4):371–9.CrossRef Zheng L, Kimura F, Wu D, Morimune A, Niwa Y, Mita S, et al. Dienogest suppresses the activation of primordial follicles and preserves the primordial follicle stockpile for fertility in mice. Reprod Biomed Online. 2018;36(4):371–9.CrossRef
23.
go back to reference Dewailly D, Andersen CY, Balen A, Broekmans F, Dilaver N, Fanchin R, et al. The physiology and clinical utility of anti-Mullerian hormone in women. Hum Reprod Update. 2014;20(3):370–85.CrossRef Dewailly D, Andersen CY, Balen A, Broekmans F, Dilaver N, Fanchin R, et al. The physiology and clinical utility of anti-Mullerian hormone in women. Hum Reprod Update. 2014;20(3):370–85.CrossRef
24.
go back to reference Knight PG, Glister C. TGF-beta superfamily members and ovarian follicle development. Reproduction. 2006;132(2):191–206.CrossRef Knight PG, Glister C. TGF-beta superfamily members and ovarian follicle development. Reproduction. 2006;132(2):191–206.CrossRef
25.
go back to reference Oktay K, Newton H, Mullan J, Gosden RG. Development of human primordial follicles to antral stages in SCID/hpg mice stimulated with follicle stimulating hormone. Hum Reprod. 1998;13(5):1133–8.CrossRef Oktay K, Newton H, Mullan J, Gosden RG. Development of human primordial follicles to antral stages in SCID/hpg mice stimulated with follicle stimulating hormone. Hum Reprod. 1998;13(5):1133–8.CrossRef
26.
go back to reference Rice S, Ojha K, Whitehead S, Mason H. Stage-specific expression of androgen receptor, follicle-stimulating hormone receptor, and anti-Mullerian hormone type II receptor in single, isolated, human preantral follicles: relevance to polycystic ovaries. J Clin Endocrinol Metab. 2007;92(3):1034–40.CrossRef Rice S, Ojha K, Whitehead S, Mason H. Stage-specific expression of androgen receptor, follicle-stimulating hormone receptor, and anti-Mullerian hormone type II receptor in single, isolated, human preantral follicles: relevance to polycystic ovaries. J Clin Endocrinol Metab. 2007;92(3):1034–40.CrossRef
Metadata
Title
Impact of perioperative use of GnRH agonist or dienogest on ovarian reserve after cystectomy for endometriomas: a randomized controlled trial
Authors
Ayako Muraoka
Satoko Osuka
Atsushi Yabuki
Bayasula
Masato Yoshihara
Hideaki Tanaka
Reina Sonehara
Natsuki Miyake
Mayuko Murakami
Sayako Yoshita
Natsuki Nakanishi
Tomoko Nakamura
Maki Goto
Akira Iwase
Hiroaki Kajiyama
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Reproductive Biology and Endocrinology / Issue 1/2021
Electronic ISSN: 1477-7827
DOI
https://doi.org/10.1186/s12958-021-00866-2

Other articles of this Issue 1/2021

Reproductive Biology and Endocrinology 1/2021 Go to the issue